CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

AstraZeneca trial shows reduced risk of severe Covid or death

By Jenny McCall

07:35, 11 October 2021

Image of an AstraZeneca Covid-19 vaccine injectible
AstraZeneca drug cocktail succeeds in phase three trial – Photo: Shutterstock

British-Swedish multinational pharmaceutical and biotechnology company AstraZeneca reported positive results from its phase three Covid-19 trials.

The group announced on Monday that its treatment trial had shown AstraZeneca’s AZD7442, a long-acting antibody (LAAB) combination, achieved a significant reduction in severe disease or death, compared to a placebo in non-hospitalised patients with mild-to-moderate symptomatic Covid-19.

“The trial met the primary endpoint, with a dose of 600mg of AZD7442 given by intramuscular (IM) injection reducing the risk of developing severe Covid-19 or death (from any cause) by 50% compared to placebo in outpatients who had been symptomatic for seven days or less,” the statement noted.

The trial also found that in a prespecified analysis of participants who received treatment within five days of symptoms occurring, AZD7442 reduced the risk of developing severe disease or death by 67%, compared to a placebo.

Combating Covid 19

AZD7442 is the first LAAB with phase three data to demonstrate benefit in both prophylaxis and treatment of Covid-19, which can be easily administered by an IM injection.

Oil - Crude

78.10 Price
-0.010% 1D Chg, %
Long position overnight fee 0.0219%
Short position overnight fee -0.0439%
Overnight fee time 22:00 (UTC)
Spread 0.030


0.60 Price
+3.380% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168


17,860.50 Price
+0.310% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 1.8


62,739.05 Price
+3.730% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

“With continued cases of serious Covid 19 infections across the globe, there is a significant need for new therapies like AZD7442 that can be used to protect vulnerable populations from getting Covid 19 and can also help prevent progression to severe disease,” said Hugh Montgomery, Professor of Intensive Care Medicine at University College London. 

“These positive results show that a convenient intramuscular dose of AZD7442 could play an important role in helping combat this devastating pandemic,” he added.

The stock price for AstraZeneca was up 0.08% in early morning trade today.

Read more: Brussels court rejects EU demand on AstraZeneca vaccines

Markets in this article

AstraZeneca - GBP
102.17 USD
-1.24 -1.200%

Related topics

Rate this article

Capital Com is an execution-only service provider. The material provided on this website is for information purposes only and should not be understood as an investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page then you do so entirely on your own risk.

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading